Nonmelanoma skin cancer in organ transplant patients

Transplantation

Volumn 75, Issue 3, 2003, Pages 253-257

  Jemec, Gregor B E ^a   Holm, Elisabeth A ^a  

^a ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; EFLORNITHINE; ETRETIN; FLUOROURACIL; IMIQUIMOD; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; RETINOL; SELENIUM; SILYMARIN;

CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MALAISE; MEDICAL SPECIALIST; MEDICAL TECHNOLOGY; MELANOMA; ORGAN TRANSPLANTATION; OUTPATIENT DEPARTMENT; PRECANCER; PRIORITY JOURNAL; PUBLISHING; REVIEW; SKIN CANCER; TEA; TUMOR;

HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KIDNEY TRANSPLANTATION; SKIN NEOPLASMS;

EID: 0037442165     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000044135.92850.75     Document Type: Review

References (54)

1. Scandinavian Transplantation Registry. Skejby Sygehus, Århus, Denmark. 2002.
2. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 147-158.
3. Ramsay HM, Fryer AA, Reece SM, et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-176.
4. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102: 111222-227.
5. Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27-34.
6. Lindelof B, Sigurgeirsson B, Gabel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143:513-519.
7. Bouwes Bavinck JN, Hardie DR, et al. The rise of skin cancer in renal transplant patients in Queensland, Australia: A follow-up. Transplantation 1996; 61: 715-721.
8. Sheil AG, Disney AP, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-1384.
9. Fortina AB, Caforio AL, Piasenico S, et al. Skin cancer in heart transplant recipients: Frequency and risk factor analysis. J Heart Lung Transplant 2000; 19: 249-255.
10. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267: 3305-3310.
11. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-509.
12. Schreiber MM, Moon TE, Fox SH, et al. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990; 23: 1114-1118.
13. Espana A, Redondo P, Fernandez AL, et al. Skin cancer in heart transplant patients. J Am Acad Dermatol 1995; 32: 458-465.
14. Osterlind A, Hjalgrim H, Kulinsky B, et al. Skin cancer as a cause of death in Denmark. Br J Dermatol 1991; 125: 580-582.
15. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999; 85: 1758-1764.
16. Gjersvik PJ. Photodynamic therapy - promising or overpraised? Tidsskr Nor Laegeforen 2000; 120: 2243.
17. Otley CC, Coldiron BM, Stasko T, et al. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137: 459-463.
18. Whited JD, Hall RP. Diagnostic accuracy and precision in assessing dermatologic disease. Problem or promise? Arch Dermatol 1997; 133: 1409-1415.
19. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratosis before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol 2001; 137: 1055-1058.
20. Harden PN, Reece SM, Fryer AA, et al. Skin cancer surveillance in renal transplant recipients: questionnaire survey of current UK practice. Br Med J 2002; 323: 600.
21. Na R, Stender IM, Wulf HC. Can autofluorescence demarcate basal cell carcinoma from normal skin? A comparison with protoporphyrin IX fluorescence. Acta Derm Venereol 2001; 81: 246-249.
22. Gniadecka M, Wulf HC, Nielsen OF, et al. Distinctive molecular abnormalities in benign and malignant skin lesions: studies by Raman spectroscopy. Photochem Photobiol 1997; 66: 418-423.
23. Hanlon EB, Manoharan R, Koo TW, et al. Prospects for in vivo Raman spectroscopy. Phys Med Biol 2000; 45: R1-59.
24. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 1997; 133: 727-732.
25. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-2308.
26. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813.
27. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050-1053.
28. Friedman HI, Williams T, Zamora S, et al. Recurrent basal cell carcinoma in margin-positive tumors. Ann Plast Surg 1997; 38: 232-235.
29. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol 1997; 38(suppl 1): S1-6.
30. Green A, Whiteman D, Frost C, et al. Sun exposure, skin cancers and related skin conditions. J Epidemiol 1999; 9: S7-13.
31. Bavinck JN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993; 129: 242-249.
32. van Zuuren EJ, Posma AN, Scholtens RE, et al. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994; 31: 760-764.
33. Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422: 185-190.
34. van Dam RM, Huang Z, Giovannucci E, et al. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000; 71: 135-141.
35. Hakim IA, Harris RB, Weisgerber UM. Tea intake and squamous cell carcinoma of the skin: influence of type of tea beverages. Cancer Epidemiol Biomarkers Prev 2000; 9: 727-731.
36. Ahmad N, Mukhtar H. Cutaneous photochemoprotection by green tea: a brief review. Skin Pharmacol Appl Skin Physiol 2001; 14: 69-76.
37. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9: 1281-1286.
38. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta-carotene to prevent basal cell and squamous cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323: 789-795.
39. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-1637.
40. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-660.
41. Lutzow-Holm C. Vitamin A as an antidote against skin cancer? Tidsskr Nor Laegeforen 1999; 119: 4161.
42. Littlewood M, Murray DS. A clinical trial of the use of 5-fluouracil in the treatment of some cutaneous malignancies. Br J Plast Surg 1973; 26: 140-146.
43. Almeida Goncalves JC, De Noronha T. 5-fluouracil (5-FU) ointment in the treatment of skin tumours and keratoses. Dermatologica 1970; 140(suppl): 97.
44. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997; 36: 72-77.
45. Shiell A. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma. Australas J Dermatol 1994; 35: 71-75.
46. Garland SM, Sellors JW, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label, multicenter phase IIIB trial. Int J STD AIDS 2001; 12: 722-729.
47. Cerburkovas O, Krause M, Ulrich J, et al. [Disseminated actinic keratosis. Comparison of topical photodynamic therapy with 5-aminolevulinic acid and topical 5% imiquimod cream]. Hautarzt 2001; 52: 942-946.
48. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiguimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
49. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002; 46: 545-548.
50. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27: 561-564.
51. Brash DE, Seetharam S, Kraemer KH, et al. Photoproduct frequency is not the major determinant of UV base substitution hot spots or cold spots in human cells. Proc Natl Acad Sci U S A 1987; 84: 3782-3786.
52. Seetharam S, Protic-Sabljic M, Seidman MM, et al. Abnormal ultraviolet mutagenic spectrum in plasmid DNA replicated in cultured fibroblasts from a patient with the skin cancer-prone disease, xeroderma pigmentosum. J Clin Invest 1987; 80: 1613-1617.
53. Kraemer KH. Dysplastic nevi, melanoma and sunlight. Photodermatol 1987; 4: 227-229.
54. Ramrakha-Jones. Transplant patients need to be made aware of skin cancer risk. Br Med J 2002: 296-296.